Hudson Bay Capital Management LP Has $19.95 Million Stock Holdings in Icon Plc $ICLR

Hudson Bay Capital Management LP trimmed its position in Icon Plc (NASDAQ:ICLR) by 40.9% during the third quarter, Holdings Channel reports. The firm owned 114,000 shares of the medical research company’s stock after selling 79,000 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Icon were worth $19,950,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Allworth Financial LP raised its stake in Icon by 64.4% in the second quarter. Allworth Financial LP now owns 1,396 shares of the medical research company’s stock valued at $203,000 after buying an additional 547 shares during the period. Geode Capital Management LLC boosted its stake in shares of Icon by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 84,370 shares of the medical research company’s stock worth $12,272,000 after acquiring an additional 2,159 shares during the period. SG Americas Securities LLC boosted its stake in shares of Icon by 12.3% during the 2nd quarter. SG Americas Securities LLC now owns 15,962 shares of the medical research company’s stock worth $2,322,000 after acquiring an additional 1,743 shares during the period. Raiffeisen Bank International AG increased its holdings in shares of Icon by 7.1% during the 2nd quarter. Raiffeisen Bank International AG now owns 7,500 shares of the medical research company’s stock worth $1,094,000 after acquiring an additional 500 shares during the last quarter. Finally, Portside Wealth Group LLC increased its holdings in shares of Icon by 11.9% during the 2nd quarter. Portside Wealth Group LLC now owns 1,816 shares of the medical research company’s stock worth $264,000 after acquiring an additional 193 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on ICLR shares. Jefferies Financial Group set a $135.00 price target on Icon and gave the company a “buy” rating in a report on Monday, February 23rd. Bank of America reiterated an “underperform” rating and issued a $75.00 price objective on shares of Icon in a report on Thursday, February 12th. Barclays cut their target price on shares of Icon from $200.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday, March 9th. Mizuho set a $216.00 target price on shares of Icon in a report on Friday, January 9th. Finally, Rothschild & Co Redburn set a $100.00 price target on shares of Icon and gave the company a “neutral” rating in a report on Tuesday, February 17th. Six equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Icon presently has a consensus rating of “Hold” and a consensus target price of $146.80.

Icon Stock Performance

Shares of NASDAQ ICLR opened at $97.14 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The firm has a market cap of $7.85 billion, a price-to-earnings ratio of 13.14, a P/E/G ratio of 2.57 and a beta of 1.35. The stock’s fifty day moving average price is $137.95 and its two-hundred day moving average price is $163.84. Icon Plc has a one year low of $66.57 and a one year high of $211.00.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.